On January 6, 2022 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022 (Press release, Enveric Biosciences, JAN 6, 2022, https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-the-hc-wainwright-bioconnect-conference-on-january-10-13-2022-301455883.html [SID1234598382]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tucker’s corporate presentation will be available on-demand starting Monday, January 10th. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at [email protected], or KCSA Strategic Communications at [email protected].

On January 6, 2022 DURECT Corporation (Nasdaq: DRRX) reported that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022 (Press release, DURECT, JAN 6, 2022, https://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-hc-wainwright-bioconnect-conference-301455647.html [SID1234598381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

H.C. Wainwright Bioconnect Conference

Date:

January 10-13, 2022

Time:

On demand starting at 7:00 A.M. Eastern Standard Time

Webcast:

View Source

The webcast link of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

On January 6, 2022 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference (Press release, Xencor, JAN 6, 2022, View Source [SID1234598380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The on-demand recording will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com beginning Monday, January 10, 2022 at 4:00 a.m. PT and will be available on the website for at least 30 days.

On January 6, 2022 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that its Chairman and Chief Executive Officer, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company’s growth and vision for the sixth consecutive year at the 40th Annual J.P. Morgan Healthcare Conference (Press release, Quanterix, JAN 6, 2022, View Source [SID1234598379]). Hrusovsky’s session will take place on Thursday, Jan. 13, 2022, at 8:15 a.m., EST (5:15 a.m., PST) and will be made available to attendees and the general public. In addition to Hrusovsky’s session, he will also be hosting one-on-one meetings with institutional investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information

To access the live webcast of Quanterix’ presentation at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 13, 2022 at 8:15 a.m., EST (5:15 a.m., PST), please visit: View Source;kiosk=true

Replays of the webcasts will be available for a limited period following the conferenc

On January 6, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that Neil Klompas, Zymeworks’ Chief Operating Officer and Chief Financial Officer, will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 at 9:45 a.m. ET (Press release, Zymeworks, JAN 6, 2022, View Source [SID1234598378]). The presentation will be webcast live and available for replay on Zymeworks’ website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!